• Tiziana Life Sciences will discuss previously announced Phase 2a INFORM-MS results for intranasal foralumab at an investor call on November 9, 2026.
• The lower dose significantly reduced brain inflammation in non-active secondary progressive multiple sclerosis, meeting the trial's efficacy endpoint.
• Both doses produced clinically meaningful fatigue improvements from baseline over 12 weeks, though the trial was not powered for this endpoint.
• Both doses were well tolerated; all 48 participants completed treatment, with no study-drug-related serious adverse events.
• Detailed results will be presented at a future scientific congress, with FDA discussions planned on next development steps.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051400PRIMZONEFULLFEED9871573) on November 05, 2026, and is solely responsible for the information contained therein.